Roles of exogenous and endogenous FGF-2 in animal models of depression

Restorative Neurology and Neuroscience

Volumn 29, Issue 3, 2011, Pages 153-165

  Jarosik, J ^a   Legutko, B ^b   Werner, S ^a,c   Unsicker, K ^a,c   Halbach, O Von Bohlen ^a,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

behavior; dendritic spines; depression; FGF 2 knockout; fibroblast growth factor; Mice; neurogenesis

Indexed keywords

AMITRIPTYLINE; FIBROBLAST GROWTH FACTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORTICAL AMYGDALA; DEPRESSION; EXPERIMENTAL TEST; HIPPOCAMPUS; LOCOMOTION; MALE; MOUSE; NERVE CELL NECROSIS; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; OLFACTORY BULBECTOMY; OPEN FIELD TEST; PASSIVE AVOIDANCE; PRIORITY JOURNAL; PYRIFORM CORTEX; TAIL SUSPENSION TEST;

AMITRIPTYLINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; AVOIDANCE LEARNING; BRAIN; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; FIBROBLAST GROWTH FACTOR 2; HINDLIMB SUSPENSION; HUMANS; IMMOBILITY RESPONSE, TONIC; INDOLES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROTUBULE-ASSOCIATED PROTEINS; MOTOR ACTIVITY; NEUROPEPTIDES; OLFACTORY BULB; ORGANIC CHEMICALS; SILVER STAINING;

EID: 79959195511     PISSN: 09226028     EISSN: 18783627     Source Type: Journal    
DOI: 10.3233/RNN-2011-0588     Document Type: Article

References (55)

1. Bachis, A., Mallei, A., Cruz, M.I., Wellstein, A. & Mocchetti, I. (2008). Chronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neurons. Neuropharmacology, 55, 1114-1120.
2. Baryshnikova, L.M., von Bohlen Und Halbach, O., Kaplan, S. & von Bartheld, C.S. (2006). Two distinct events, section compression and loss of particles (?lost caps?), contribute to z-axis distortion and bias in optical disector counting. Microsc Res Tech, 69, 738-756. (Pubitemid 44380012)
3. Berton, O. & Nestler, E.J. (2006). New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci, 7, 137-151. (Pubitemid 43151600)
4. Bland, S.T., Tamlyn, J.P., Barrientos, R.M., Greenwood, B.N., Watkins, L.R., Campeau, S., Day, H.E. & Maier, S.F. (2007). Expression of fibroblast growth factor-2 and brain-derived neurotrophic factor mRNA in the medial prefrontal cortex and hippocampus after uncontrollable or controllable stress. Neuroscience, 144, 1219-1228. (Pubitemid 46123824)
5. Carlsen, J., De Olmos, J.&Heimer,L. (1982).Tracing of two-neuron pathways in the olfactory system by the aid of transneuronal degeneration: projections to the amygdaloid body and hippocampal formation. J Comp Neurol, 208, 196-208. (Pubitemid 12041234)
6. Chen, H., Pandey, G.N. & Dwivedi, Y. (2006). Hippocampal cell proliferation regulation by repeated stress and antidepressants. NeuroReport, 17, 863-867. (Pubitemid 43869948)
7. Coudore, F., Fialip, J., Eschalier, A. & Lavarenne, J. (1994). Mice plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after half-life repeated administration. Comparison with acute administration. Fundam Clin Pharmacol, 8, 525-531.
8. Cryan, J.F.&Mombereau, C. (2004). In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry, 9, 326-357. (Pubitemid 38534696)
9. Cryan, J.F., Mombereau, C. & Vassout, A. (2005). The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev, 29, 571-625. (Pubitemid 40755457)
10. Dono, R., Texido, G., Dussel, R., Ehmke, H. & Zeller, R. (1998). Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice. EMBO J, 17, 4213-4225. (Pubitemid 28362612)
11. Evans, S.J., Choudary, P.V., Neal, C.R., Li, J.Z., Vawter, M.P., Tomita, H., Lopez, J.F., Thompson, R.C., Meng, F., Stead, J.D., Walsh, D.M., Myers, R.M., Bunney,W.E.,Watson, S.J., Jones, E.G. & Akil, H. (2004). Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci U S A, 101, 15506-15511. (Pubitemid 39441571)
12. Gaughran, F., Payne, J., Sedgwick, P.M., Cotter, D. & Berry, M. (2006). Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Res Bull, 70, 221-227. (Pubitemid 44067346)
13. Graham, B.M. & Richardson, R. (2010). Fibroblast growth factor-2 enhances extinction and reduces renewal of conditioned fear. Neuropsychopharmacology, 35, 1348-1355.
14. Hellweg, R., Zueger, M., Fink, K., Hortnagl, H. & Gass, P. (2007). Olfactory bulbectomy in mice leads to increased BDNF levels and decreased serotonin turnover in depression-related brain areas. Neurobiol Dis, 25, 1-7. (Pubitemid 44773792)
15. Henn, F.A. & Vollmayr, B. (2005). Stress models of depression: forming genetically vulnerable strains. Neurosci Biobehav Rev, 29, 799-804. (Pubitemid 40755465)
16. Jang, S.W., Liu, X., Chan, C.B., Weinshenker, D., Hall, R.A., Xiao, G. & Ye, K. (2009). Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem Biol, 16, 644-656.
17. Jarosik, J., Legutko, B., Dono, R., Unsicker, K. & von Bohlen Und Halbach, O. (2007). Antidepressant-mediated reversal of abnormal behaviour and neurodegeneration in mice following olfactory bulbectomy. Exp Neurol, 204, 20-28. (Pubitemid 46330253)
18. Jesberger, J.A. & Richardson, J.S. (1985). Neurochemical aspects of depression: the past and the future? Int J Neurosci, 27, 19-47.
19. Kato, M., Okugawa, G., Wakeno, M., Takekita, Y., Nonen, S., Tetsuo, S., Nishida, K., Azuma, J., Kinoshita, T. & Serretti, A. (2009). Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. Eur Neuropsychopharmacol, 19, 718-725.
20. Keilhoff, G., Becker, A., Grecksch, G., Bernstein, H.G. & Wolf, G. (2006). Cell proliferation is influenced by bulbectomy and normalized by imipramine treatment in a region-specific manner. Neuropsychopharmacology, 31, 1165-1176. (Pubitemid 43971834)
21. Kelly, J.P., Wrynn, A.S. & Leonard, B.E. (1997). The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther, 74, 299-316. (Pubitemid 27425352)
22. Kiprianova, I., Schindowski, K., von Bohlen Und Halbach, O., Krause, S., Dono, R., Schwaninger, M. & Unsicker, K. (2004). Enlarged infarct volume and loss of BDNF mRNA induction following brain ischemia in mice lacking FGF-2. Exp Neurol, 189, 252-260. (Pubitemid 39221820)
23. Leonard, B.E. & Tuite, M. (1981). Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat. Int Rev Neurobiol, 22, 251-286.
24. Malberg, J.E., Eisch, A.J., Nestler, E.J. & Duman, R.S. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci, 20, 9104-9110. (Pubitemid 32042912)
25. Mallei, A., Shi, B. & Mocchetti, I. (2002). Antidepressant treatments induce the expression of basic fibroblast growth factor in cortical and hippocampal neurons. Mol Pharmacol, 61, 1017-1024. (Pubitemid 34441766)
26. Maragnoli, M.E., Fumagalli, F., Gennarelli, M., Racagni, G.&Riva, M.A. (2004). Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biol Psychiatry, 55, 1095-1102. (Pubitemid 38680562)
27. Norrholm, S.D. & Ouimet, C.C. (2001). Altered dendritic spine density in animal models of depression and in response to antidepressant treatment. Synapse, 42, 151-163. (Pubitemid 32999622)
28. Nowak, G., Szewczyk, B.,Wieronska, J.M., Branski, P., Palucha, A., Pilc, A., Sadlik, K.&Piekoszewski,W. (2003). Antidepressantlike effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull, 61, 159-164. (Pubitemid 36794273)
29. Overo, K.F. (1982). Kinetics of citalopram in test animals; drug exposure in safety studies. Prog Neuropsychopharmacol Biol Psychiatry, 6, 297-309. (Pubitemid 13255332)
30. Perez, J.A., Clinton, S.M., Turner, C.A., Watson, S.J. & Akil, H. (2009). A new role for FGF2 as an endogenous inhibitor of anxiety. J Neurosci, 29, 6379-6387.
31. Pollatos, O., Albrecht, J., Kopietz, R., Linn, J., Schoepf, V., Kleemann, A.M., Schreder, T., Schandry, R. & Wiesmann, M. (2007). Reduced olfactory sensitivity in subjects with depressive symptoms. J Affect Disord, 102, 101-108. (Pubitemid 47042179)
32. Porsolt, R.D. (2000). Animal models of depression: utility for transgenic research. Rev Neurosci, 11, 53-58. (Pubitemid 30006576)
33. Reuss, B. & von Bohlen Und Halbach, O. (2003). Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res, 313, 139-157. (Pubitemid 37129946)
34. Sairanen, M., Lucas, G., Ernfors, P., Castren, M. & Castren, E. (2005). Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J Neurosci, 25, 1089-1094. (Pubitemid 40268949)
35. Schmued, L.C. & Hopkins, K.J. (2000). Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res, 874, 123-130.
36. Sibille, E. & Hen, R. (2001). Combining genetic and genomic approaches to study mood disorders. Eur Neuropsychopharmacol, 11, 413-421. (Pubitemid 33026515)
37. Siuciak, J.A., Lewis, D.R., Wiegand, S.J. & Lindsay, R.M. (1997). Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav, 56, 131-137. (Pubitemid 27016116)
38. Song, C.&Leonard, B.E. (2005). The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev, 29, 627-647. (Pubitemid 40755458)
39. Steru, L., Chermat, R., Thierry, B. & Simon, P. (1985). The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl), 85, 367-370. (Pubitemid 15123115)
40. Tadano, T., Hozumi, S., Yamadera, F., Murata, A., Niijima, F., Tan- No, K., Nakagawasai, O.&Kisara, K. (2004). Effects ofNMDA receptor-related agonists on learning and memory impairment in olfactory bulbectomized mice. Methods Find Exp Clin Pharmacol, 26, 93-97. (Pubitemid 38453709)
41. Turner, C.A., Akil, H.,Watson, S.J.&Evans, S.J. (2006). The fibroblast growth factor system and mood disorders. Biol Psychiatry, 59, 1128-1135.
42. Turner, C.A., Calvo, N., Frost, D.O., Akil, H.&Watson, S.J. (2008a). The fibroblast growth factor system is downregulated following social defeat. Neurosci Lett, 430, 147-150.
43. Turner, C.A., Gula, E.L., Taylor, L.P., Watson, S.J. & Akil, H. (2008b). Antidepressant-like effects of intracerebroventricular FGF2 in rats. Brain Res, 1224, 63-68.
44. Unsicker, K., Reichert-Preibsch, H., Schmidt, R., Pettmann, B., Labourdette, G. & Sensenbrenner, M. (1987). Astroglial and fibroblast growth factors have neurotrophic functions for cultured peripheral and central nervous system neurons. Proc Natl Acad Sci U S A, 84, 5459-5463.
45. van Riezen, H. & Leonard, B.E. (1990). Effects of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomized rats. Pharmacol Ther, 47, 21-34. (Pubitemid 20183306)
46. van Riezen, H., Schnieden, H. &Wren, A.F. (1977). Olfactory bulb ablation in the rat: behavioural changes and their reversal by antidepressant drugs. Br J Pharmacol, 60, 521-528. (Pubitemid 8149537)
47. Verwer, R.W., Sluiter, A.A., Balesar, R.A., Baayen, J.C., Noske, D.P., Dirven, C.M.,Wouda, J., van Dam, A.M., Lucassen, P.J.& Swaab, D.F. (2007). Mature astrocytes in the adult human neocortex express the early neuronal marker doublecortin. Brain, 130, 3321-3335. (Pubitemid 350209078)
48. von Bohlen Und Halbach, O. (2007). Immunohistological markers for staging neurogenesis in adult hippocampus. Cell Tissue Res, 329, 409-420. (Pubitemid 47231297)
49. von Bohlen Und Halbach, O., Krause, S., Medina, D., Sciarretta, C., Minichiello, L. & Unsicker, K. (2006a). Regional- and age-dependent reduction in trkB receptor expression in the hippocampus is associated with altered spine morphologies. Biol Psychiatry, 59, 793-800.
50. von Bohlen Und Halbach, O., Zacher, C., Gass, P. & Unsicker, K. (2006b). Age-related alterations in hippocampal spines and deficiencies in spatial memory in mice. J Neurosci Res, 83, 525-531. (Pubitemid 43384845)
51. Ye, X., Carp, R.I., Schmued, L.C. & Scallet, A.C. (2001). Fluoro- Jade and silver methods: application to the neuropathology of scrapie, a transmissible spongiform encephalopathy. Brain Res Brain Res Protoc, 8, 104-112. (Pubitemid 32973926)
52. Zechel, S., Jarosik, J., Kiprianova, I., Schober, A., Unsicker, K. & von Bohlen Und Halbach, O. (2006). FGF-2 deficiency does not alter vulnerability of the dopaminergic nigrostriatal system towards MPTP intoxication in mice. Eur J Neurosci, 23, 1671-1675.
53. Zechel, S., Werner, S., Unsicker, K. & von Bohlen Und Halbach, O. (2010). Expression and functions of fibroblast growth factor 2 (FGF-2) in hippocampal formation. Neuroscientist, 16, 357-373.
54. Zucchini, S., Barbieri, M. & Simonato, M. (2005). Alterations in seizure susceptibility and in seizure-induced plasticity after pharmacologic and genetic manipulation of the fibroblast growth factor-2 system. Epilepsia, 46(Suppl 5), 52-58. (Pubitemid 40962122)
55. Zueger, M., Urani, A., Chourbaji, S., Zacher, C., Roche, M., Harkin, A. & Gass, P. (2005). Olfactory bulbectomy in mice induces alterations in exploratory behavior. Neurosci Lett, 374, 142-146. (Pubitemid 40092213)